Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative diseases and retinal conditions.

Phase 1a trial for THN391 yields positive results

Alex Hacopian, MD, is in practice at Mann Eye Institute in Houston, Texas.

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient satisfaction following bilateral implantation of an advanced presbyopia-correcting intraocular lens.

ASCRS 2025: Visual and patient-reported outcomes following bilateral Odyssey implantation

Joseph Colcombe is a resident physician with the Department of Ophthalmology at New York University Grossman School of Medicine in New York, New York.

Videos

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration

The Residency Report: Study provides new insights into USH2A target end points

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of MINIject in patients with glaucoma with up to 5 years of follow up.

iSTAR Medical announces positive 5-year data from STAR-GLOBAL trial for MINIject

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Atlanta—CIBA Vision is hoping to attract new patients with a variety of programs, including a rebate and Super Bowl advertising.

CIBA Vision programs promote contact lenses

CIBA Vision programs promote contact lenses

Newsletter